NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trial; and NEO212, a covalently conjugated...
48 insider purchases on record · latest filing 2026-09-15.
Insiders have also filed 21 sale transactions at NTHI.